	US 12,227,560 B2
	Anti-CHIKV antibodies and uses thereof
Kara Carter, Bridgewater, NJ (US); Cendrine Lemoine, Paris (FR); Marie Mandron, Paris (FR); Sunghae Park, Bridgewater, NJ (US); Huawei Qiu, Bridgewater, NJ (US); and Jonathan Rothblatt, Bridgewater, NJ (US)
Assigned to SANOFI, Paris (FR)
Filed by SANOFI, Paris (FR)
Filed on Feb. 16, 2022, as Appl. No. 17/672,871.
Application 17/672,871 is a division of application No. 15/787,647, filed on Oct. 18, 2017, granted, now 11,286,295.
Claims priority of application No. 16306374 (EP), filed on Oct. 20, 2016.
Prior Publication US 2022/0275063 A1, Sep. 1, 2022
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/1081 (2013.01) [A61P 31/14 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/565 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); Y02A 50/30 (2018.01)]

22 Claims

1. A polynucleotide comprising a sequence encoding an isolated monoclonal antibody that binds to CHIKV and that comprises three Heavy Chain Complementary Determining Regions (CDRHs) and three Light Chain Complementary Determining Regions (CDRLs), wherein:

i. said CDRHs have amino acid sequences of SEQ ID NO: 5, 6 and 7, and said CDRLs have amino acid sequences of SEQ ID NO: 8, GNT and 10, or

ii. said CDRHs have amino acid sequences of SEQ ID NO: 11, 12 and 13, and said CDRLs have amino acid sequences of SEQ ID NO: 14, GTS and 16,

and wherein said antibody further comprises a Fc region comprising a leucine at position 428 and a serine at position 434, respectively, wherein said amino acid positions in the Fc region are given according to the EU index.